Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:08 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

ClinicalTrials.gov · NCT01796301 · Registry updated: 2022-11-29

Condition / research focus: Postmenopausal Osteoporosis
Sponsor: Amgen
Countries with listed sites: Argentina · Belgium · Canada · Colombia · Czechia · Denmark · Hungary · Poland · Spain · United Kingdom · United States
Registry dates and results: Start: 2013-01-31. Completion: 2015-05-14 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Romozosumab (drug) — also listed as: AMG 785
Teriparatide (drug) — also listed as: Forteo, Forsteo

Where the study takes place — 50 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Research Site
Gainesville, Georgia, United States
Site recruitment: Not reported
Research Site
Bethesda, Maryland, United States
Site recruitment: Not reported
Research Site
Boston, Massachusetts, United States
Site recruitment: Not reported
Research Site
Boston, Massachusetts, United States
Site recruitment: Not reported
Research Site
Detroit, Michigan, United States
Site recruitment: Not reported
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Site recruitment: Not reported
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Site recruitment: Not reported
Research Site
Córdoba, Córdoba Province, Argentina
Site recruitment: Not reported
Research Site
Genk, Belgium
Site recruitment: Not reported
Research Site
Ghent, Belgium
Site recruitment: Not reported
Research Site
Leuven, Belgium
Site recruitment: Not reported
Research Site
Liège, Belgium
Site recruitment: Not reported
Research Site
Calgary, Alberta, Canada
Site recruitment: Not reported
Research Site
Vancouver, British Columbia, Canada
Site recruitment: Not reported
Research Site
Toronto, Ontario, Canada
Site recruitment: Not reported
Research Site
Toronto, Ontario, Canada
Site recruitment: Not reported
Research Site
Québec, Quebec, Canada
Site recruitment: Not reported
Research Site
Medellín, Antioquia, Colombia
Site recruitment: Not reported
Research Site
Barranquilla, Atlántico, Colombia
Site recruitment: Not reported
Research Site
Brno, Czechia
Site recruitment: Not reported
Research Site
Ostrava, Czechia
Site recruitment: Not reported
Research Site
Pilsen, Czechia
Site recruitment: Not reported
Research Site
Praha 11 - Chodov, Czechia
Site recruitment: Not reported
Research Site
Uherské Hradiště, Czechia
Site recruitment: Not reported
Research Site
Aalborg, Denmark
Site recruitment: Not reported
Research Site
Aarhus C, Denmark
Site recruitment: Not reported
Research Site
Ballerup Municipality, Denmark
Site recruitment: Not reported
Research Site
Esbjerg, Denmark
Site recruitment: Not reported
Research Site
Hillerød, Denmark
Site recruitment: Not reported
Research Site
Hvidovre, Denmark
Site recruitment: Not reported
Research Site
Odense, Denmark
Site recruitment: Not reported
Research Site
Budapest, Hungary
Site recruitment: Not reported
Research Site
Budapest, Hungary
Site recruitment: Not reported
Research Site
Budapest, Hungary
Site recruitment: Not reported
Research Site
Gdynia, Poland
Site recruitment: Not reported
Research Site
Katowice, Poland
Site recruitment: Not reported
Research Site
Warsaw, Poland
Site recruitment: Not reported
Research Site
Wroclaw, Poland
Site recruitment: Not reported
Research Site
Granada, Andalusia, Spain
Site recruitment: Not reported
Research Site
Barcelona, Catalonia, Spain
Site recruitment: Not reported
Research Site
LHospitalet de Llobregat, Catalonia, Spain
Site recruitment: Not reported
Research Site
Pozuelo de Alarcón, Madrid, Spain
Site recruitment: Not reported
Research Site
Madrid, Spain
Site recruitment: Not reported
Research Site
Madrid, Spain
Site recruitment: Not reported
Research Site
Cardiff, United Kingdom
Site recruitment: Not reported
Research Site
Chorley, United Kingdom
Site recruitment: Not reported
Research Site
Liverpool, United Kingdom
Site recruitment: Not reported
Research Site
Northwood, United Kingdom
Site recruitment: Not reported
Research Site
Reading, United Kingdom
Site recruitment: Not reported
Research Site
Sidcup, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).

ClinicalTrials.gov · NCT04750460 · Registry updated: 2022-11-10

Condition / research focus: Secondary Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder; Dialysis; Hypocalcemia; Hypoparathyroidism
Sponsor: Saint Petersburg State University, Russia
Countries with listed sites: Russia
Registry dates and results: Start: 2021-03-01. Completion: 2022-02-16 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: Forsteo

Where the study takes place — 1 listed sites

Saint-Petersburg State University Hospital
Saint Petersburg, Russia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

ClinicalTrials.gov · NCT05164614 · Registry updated: 2022-10-31

Condition / research focus: Healthy Volunteers
Sponsor: RANI Therapeutics
Countries with listed sites: Australia
Registry dates and results: Start: 2022-02-21. Completion: 2022-10-17 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

RT-102 (80 μg) (combination_product)
Forteo (drug)
RT-102 (20 μg) (combination_product)

Where the study takes place — 1 listed sites

Nucleus Network
Melbourne, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

ClinicalTrials.gov · NCT00896532 · Registry updated: 2022-09-22

Condition / research focus: Low Bone Mineral Density; Postmenopausal Osteoporosis
Sponsor: Amgen
Countries with listed sites: No country reported
Registry dates and results: Start: 2009-06-03. Completion: 2016-02-18 (may be estimated). Results are posted in this registry.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo to Romosozumab (drug)
Alendronate (drug) — also listed as: Fosamax
Teriparatide (drug) — also listed as: Forsteo
Romosozumab (drug) — also listed as: AMG 785, EVENITY™
Denosumab (drug) — also listed as: Prolia®
Placebo to Denosumab (drug)
Zoledronic acid (drug) — also listed as: Aclasta

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial

ClinicalTrials.gov · NCT02972424 · Registry updated: 2022-07-27

Condition / research focus: Osteoporotic Fractures
Sponsor: Hospital for Special Surgery, New York
Countries with listed sites: United States
Registry dates and results: Start: 2017-05-01. Completion: 2021-07-08 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide Prefilled Syringe (drug) — also listed as: Forteo
Placebo (drug) — also listed as: Placebo prefilled syringe

Where the study takes place — 1 listed sites

Hospital for Special Surgery
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

ClinicalTrials.gov · NCT05369013 · Registry updated: 2022-05-17

Condition / research focus: Osteoporosis
Sponsor: STADA, Spain
Countries with listed sites: Spain
Registry dates and results: Start: 2021-06-15. Completion: 2024-04-14 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 10 listed sites

Hospital Parc Taulí
Barcelona, Spain
Site recruitment: Not reported
Hospital Universitario Igualada
Barcelona, Spain
Site recruitment: Not reported
Hospital 12 de Octubre
Madrid, Spain
Site recruitment: Not reported
Hospital de La Princesa
Madrid, Spain
Site recruitment: Not reported
Hospital Fundación Jimenez Diaz
Madrid, Spain
Site recruitment: Not reported
Hospital Infanta Leonor
Madrid, Spain
Site recruitment: Not reported
Instituto Palacio de Madrid
Madrid, Spain
Site recruitment: Not reported
Complejo Hospitalario Universitario de Orense
Ourense, Spain
Site recruitment: Not reported
Hospital Universitario Central de Asturias
Oviedo, Spain
Site recruitment: Not reported
Hospital Virgen Macarena
Seville, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

ClinicalTrials.gov · NCT00754442 · Registry updated: 2022-04-01

Condition / research focus: Secondary Hyperparathyroidism
Sponsor: University of Maryland, Baltimore
Countries with listed sites: United States
Registry dates and results: Start: 2007-02. Completion: 2008-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: Forteo

Where the study takes place — 1 listed sites

University of Maryland School of Medicine Division of Endocrinology
Baltimore, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Norwegian Capture the Fracture Initiative

ClinicalTrials.gov · NCT02536898 · Registry updated: 2022-03-22

Condition / research focus: Hip Fracture; Vertebral Fracture; Other Low-trauma Fracture
Sponsor: Oslo University Hospital
Countries with listed sites: Norway
Registry dates and results: Start: 2015-05. Completion: 2020-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fracture Liaison Service (other)
Current treatment (other)

Where the study takes place — 7 listed sites

Haukeland University Hospital
Bergen, Norway
Site recruitment: Not reported
Drammen Hospital
Drammen, Norway
Site recruitment: Not reported
Molde Hospital
Molde, Norway
Site recruitment: Not reported
Oslo University Hospital
Oslo, Norway
Site recruitment: Not reported
Bærum Hospital
Sandvika, Norway
Site recruitment: Not reported
University Hospital of North Norway
Tromsø, Norway
Site recruitment: Not reported
St. Olavs University Hospital
Trondheim, Norway
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

ClinicalTrials.gov · NCT03702140 · Registry updated: 2021-09-21

Condition / research focus: Osteoporosis
Sponsor: Shinshu University
Countries with listed sites: Japan
Registry dates and results: Start: 2018-10-09. Completion: 2025-10-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

"Teriparatide", "Forteo® or Teribon" (drug)

Where the study takes place — 1 listed sites

Yukio Nakamura
Matsumoto, Nagano, Japan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture

ClinicalTrials.gov · NCT05018637 · Registry updated: 2021-08-24

Condition / research focus: Vertebral Compression Fracture; Osteoporotic Fractures
Sponsor: Inbo Han
Countries with listed sites: South Korea
Registry dates and results: Start: 2020-09-01. Completion: 2022-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

WJ-MSC (drug) — also listed as: teriparatide
Teriparatide (drug)

Where the study takes place — 1 listed sites

CHA University, CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes

ClinicalTrials.gov · NCT04921124 · Registry updated: 2021-08-12

Condition / research focus: Stress Fracture
Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2021-05-24. Completion: 2021-07-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug)

Where the study takes place — 1 listed sites

Norfolk and Norwich University Hospitals Foundation Trust
Norwich, Norfolk, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot

ClinicalTrials.gov · NCT02023411 · Registry updated: 2021-06-30

Condition / research focus: Diabetic Neuropathic Arthropathy
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Countries with listed sites: India
Registry dates and results: Start: 2014-01. Completion: 2018-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: parathyroid hormone, recombinant human parathyroid hormone
Placebo (other)

Where the study takes place — 2 listed sites

Deptt of Endocrinology
Chandigarh, India
Site recruitment: Not reported
PGIMER
Chandigarh, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

ClinicalTrials.gov · NCT02824718 · Registry updated: 2021-06-28

Condition / research focus: Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment
Sponsor: Assistance Publique - Hôpitaux de Paris
Countries with listed sites: France
Registry dates and results: Start: 2017-06-06. Completion: 2020-05-28 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: FORSTEO
Thiazide (drug) — also listed as: ESIDREX
Potassium sparing diuretic (drug) — also listed as: MODAMIDE
Alfacalcidol (drug) — also listed as: UN-ALFA

Where the study takes place — 1 listed sites

AP-HP Hopital Europeen Georges Pompidou
Paris, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass

ClinicalTrials.gov · NCT04003467 · Registry updated: 2021-06-28

Condition / research focus: Osteoporosis
Sponsor: Entera Bio Ltd.
Countries with listed sites: Israel
Registry dates and results: Start: 2019-06-30. Completion: 2021-05-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

EBP05 (drug) — also listed as: hPTH(1-34), Teriparatide
Placebo of EBP05 (drug) — also listed as: Placebo

Where the study takes place — 4 listed sites

Hadassah Medical Center, Mt. Scopus Hospital
Jerusalem, Israel
Site recruitment: Not reported
Rabin Medical Center, Beilinson Campus
Petah Tikva, Israel
Site recruitment: Not reported
Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

ClinicalTrials.gov · NCT01679080 · Registry updated: 2021-06-25

Condition / research focus: Osteogenesis Imperfecta
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2012-11. Completion: 2021-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Zoledronic acid (drug) — also listed as: zolendronate, Aclasta
Teriparatide (drug) — also listed as: PTH, Forsteo
No active treatment (other)

Where the study takes place — 3 listed sites

Osteoporosis clinic; department of endocrinology and metabolism
Aarhus, Aarhus C, Denmark
Site recruitment: Not reported
Department of endocrinology
Hvidovre, Denmark
Site recruitment: Not reported
Department of Endocrinology M
Odense, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

ClinicalTrials.gov · NCT01292252 · Registry updated: 2021-05-03

Condition / research focus: Lumbar Spondylosis; Lumbar Spondylolisthesis; Adult Degenerative Lumbar Scoliosis
Sponsor: Shane Burch
Countries with listed sites: United States
Registry dates and results: Start: 2011-08. Completion: 2016-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

teriparatide (biological) — also listed as: Forteo, recombinant human parathyroid hormone (1-34)
Placebo (biological)

Where the study takes place — 1 listed sites

UCSF Spine Center
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults

ClinicalTrials.gov · NCT04747392 · Registry updated: 2021-02-10

Condition / research focus: Postmenopausal Osteoporosis
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2020-08-19. Completion: 2020-11-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SAL001 (biological)
FORSTEO (biological)

Where the study takes place — 1 listed sites

The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

ClinicalTrials.gov · NCT02176382 · Registry updated: 2021-02-09

Condition / research focus: Postmenopausal Osteoporosis
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2014-08. Completion: 2020-02 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

denosumab (drug) — also listed as: Prolia
teriparatide (drug) — also listed as: Forteo
Zoledronic acid (drug) — also listed as: Reclast

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Circulating Myokine Levels and Bone Metabolism

ClinicalTrials.gov · NCT04206618 · Registry updated: 2021-01-12

Condition / research focus: Osteoporosis, Postmenopausal
Sponsor: 424 General Military Hospital
Countries with listed sites: Greece
Registry dates and results: Start: 2019-06-01. Completion: 2020-11-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: rhPTH 1-34
Denosumab (drug) — also listed as: RANKL inhibitor

Where the study takes place — 1 listed sites

424 General Military Hospital
Thessaloniki, Northern Greece, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders

ClinicalTrials.gov · NCT02252679 · Registry updated: 2020-11-06

Condition / research focus: Bone Diseases; Osteomalacia; Osteoporosis
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium · Germany
Registry dates and results: Start: 2014-10. Completion: 2018-12 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 2 listed sites

UZ Leuven
Leuven, Belgium
Site recruitment: Not reported
GEOMAR-Helmholtz Centre for Ocean Research
Kiel, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:08 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

ClinicalTrials.gov · NCT01796301 · Registry updated: 2022-11-29

Condition / research focus: Postmenopausal Osteoporosis
Sponsor: Amgen
Countries with listed sites: Argentina · Belgium · Canada · Colombia · Czechia · Denmark · Hungary · Poland · Spain · United Kingdom · United States
Registry dates and results: Start: 2013-01-31. Completion: 2015-05-14 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Romozosumab (drug) — also listed as: AMG 785
Teriparatide (drug) — also listed as: Forteo, Forsteo

Where the study takes place — 50 listed sites

Research Site
Gainesville, Georgia, United States
Site recruitment: Not reported
Research Site
Bethesda, Maryland, United States
Site recruitment: Not reported
Research Site
Boston, Massachusetts, United States
Site recruitment: Not reported
Research Site
Boston, Massachusetts, United States
Site recruitment: Not reported
Research Site
Detroit, Michigan, United States
Site recruitment: Not reported
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Site recruitment: Not reported
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Site recruitment: Not reported
Research Site
Córdoba, Córdoba Province, Argentina
Site recruitment: Not reported
Research Site
Genk, Belgium
Site recruitment: Not reported
Research Site
Ghent, Belgium
Site recruitment: Not reported
Research Site
Leuven, Belgium
Site recruitment: Not reported
Research Site
Liège, Belgium
Site recruitment: Not reported
Research Site
Calgary, Alberta, Canada
Site recruitment: Not reported
Research Site
Vancouver, British Columbia, Canada
Site recruitment: Not reported
Research Site
Toronto, Ontario, Canada
Site recruitment: Not reported
Research Site
Toronto, Ontario, Canada
Site recruitment: Not reported
Research Site
Québec, Quebec, Canada
Site recruitment: Not reported
Research Site
Medellín, Antioquia, Colombia
Site recruitment: Not reported
Research Site
Barranquilla, Atlántico, Colombia
Site recruitment: Not reported
Research Site
Brno, Czechia
Site recruitment: Not reported
Research Site
Ostrava, Czechia
Site recruitment: Not reported
Research Site
Pilsen, Czechia
Site recruitment: Not reported
Research Site
Praha 11 - Chodov, Czechia
Site recruitment: Not reported
Research Site
Uherské Hradiště, Czechia
Site recruitment: Not reported
Research Site
Aalborg, Denmark
Site recruitment: Not reported
Research Site
Aarhus C, Denmark
Site recruitment: Not reported
Research Site
Ballerup Municipality, Denmark
Site recruitment: Not reported
Research Site
Esbjerg, Denmark
Site recruitment: Not reported
Research Site
Hillerød, Denmark
Site recruitment: Not reported
Research Site
Hvidovre, Denmark
Site recruitment: Not reported
Research Site
Odense, Denmark
Site recruitment: Not reported
Research Site
Budapest, Hungary
Site recruitment: Not reported
Research Site
Budapest, Hungary
Site recruitment: Not reported
Research Site
Budapest, Hungary
Site recruitment: Not reported
Research Site
Gdynia, Poland
Site recruitment: Not reported
Research Site
Katowice, Poland
Site recruitment: Not reported
Research Site
Warsaw, Poland
Site recruitment: Not reported
Research Site
Wroclaw, Poland
Site recruitment: Not reported
Research Site
Granada, Andalusia, Spain
Site recruitment: Not reported
Research Site
Barcelona, Catalonia, Spain
Site recruitment: Not reported
Research Site
LHospitalet de Llobregat, Catalonia, Spain
Site recruitment: Not reported
Research Site
Pozuelo de Alarcón, Madrid, Spain
Site recruitment: Not reported
Research Site
Madrid, Spain
Site recruitment: Not reported
Research Site
Madrid, Spain
Site recruitment: Not reported
Research Site
Cardiff, United Kingdom
Site recruitment: Not reported
Research Site
Chorley, United Kingdom
Site recruitment: Not reported
Research Site
Liverpool, United Kingdom
Site recruitment: Not reported
Research Site
Northwood, United Kingdom
Site recruitment: Not reported
Research Site
Reading, United Kingdom
Site recruitment: Not reported
Research Site
Sidcup, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).

ClinicalTrials.gov · NCT04750460 · Registry updated: 2022-11-10

Condition / research focus: Secondary Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder; Dialysis; Hypocalcemia; Hypoparathyroidism
Sponsor: Saint Petersburg State University, Russia
Countries with listed sites: Russia
Registry dates and results: Start: 2021-03-01. Completion: 2022-02-16 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: Forsteo

Where the study takes place — 1 listed sites

Saint-Petersburg State University Hospital
Saint Petersburg, Russia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

ClinicalTrials.gov · NCT05164614 · Registry updated: 2022-10-31

Condition / research focus: Healthy Volunteers
Sponsor: RANI Therapeutics
Countries with listed sites: Australia
Registry dates and results: Start: 2022-02-21. Completion: 2022-10-17 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

RT-102 (80 μg) (combination_product)
Forteo (drug)
RT-102 (20 μg) (combination_product)

Where the study takes place — 1 listed sites

Nucleus Network
Melbourne, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

ClinicalTrials.gov · NCT00896532 · Registry updated: 2022-09-22

Condition / research focus: Low Bone Mineral Density; Postmenopausal Osteoporosis
Sponsor: Amgen
Countries with listed sites: No country reported
Registry dates and results: Start: 2009-06-03. Completion: 2016-02-18 (may be estimated). Results are posted in this registry.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo to Romosozumab (drug)
Alendronate (drug) — also listed as: Fosamax
Teriparatide (drug) — also listed as: Forsteo
Romosozumab (drug) — also listed as: AMG 785, EVENITY™
Denosumab (drug) — also listed as: Prolia®
Placebo to Denosumab (drug)
Zoledronic acid (drug) — also listed as: Aclasta

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial

ClinicalTrials.gov · NCT02972424 · Registry updated: 2022-07-27

Condition / research focus: Osteoporotic Fractures
Sponsor: Hospital for Special Surgery, New York
Countries with listed sites: United States
Registry dates and results: Start: 2017-05-01. Completion: 2021-07-08 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide Prefilled Syringe (drug) — also listed as: Forteo
Placebo (drug) — also listed as: Placebo prefilled syringe

Where the study takes place — 1 listed sites

Hospital for Special Surgery
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

ClinicalTrials.gov · NCT05369013 · Registry updated: 2022-05-17

Condition / research focus: Osteoporosis
Sponsor: STADA, Spain
Countries with listed sites: Spain
Registry dates and results: Start: 2021-06-15. Completion: 2024-04-14 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 10 listed sites

Hospital Parc Taulí
Barcelona, Spain
Site recruitment: Not reported
Hospital Universitario Igualada
Barcelona, Spain
Site recruitment: Not reported
Hospital 12 de Octubre
Madrid, Spain
Site recruitment: Not reported
Hospital de La Princesa
Madrid, Spain
Site recruitment: Not reported
Hospital Fundación Jimenez Diaz
Madrid, Spain
Site recruitment: Not reported
Hospital Infanta Leonor
Madrid, Spain
Site recruitment: Not reported
Instituto Palacio de Madrid
Madrid, Spain
Site recruitment: Not reported
Complejo Hospitalario Universitario de Orense
Ourense, Spain
Site recruitment: Not reported
Hospital Universitario Central de Asturias
Oviedo, Spain
Site recruitment: Not reported
Hospital Virgen Macarena
Seville, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

ClinicalTrials.gov · NCT00754442 · Registry updated: 2022-04-01

Condition / research focus: Secondary Hyperparathyroidism
Sponsor: University of Maryland, Baltimore
Countries with listed sites: United States
Registry dates and results: Start: 2007-02. Completion: 2008-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: Forteo

Where the study takes place — 1 listed sites

University of Maryland School of Medicine Division of Endocrinology
Baltimore, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Norwegian Capture the Fracture Initiative

ClinicalTrials.gov · NCT02536898 · Registry updated: 2022-03-22

Condition / research focus: Hip Fracture; Vertebral Fracture; Other Low-trauma Fracture
Sponsor: Oslo University Hospital
Countries with listed sites: Norway
Registry dates and results: Start: 2015-05. Completion: 2020-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fracture Liaison Service (other)
Current treatment (other)

Where the study takes place — 7 listed sites

Haukeland University Hospital
Bergen, Norway
Site recruitment: Not reported
Drammen Hospital
Drammen, Norway
Site recruitment: Not reported
Molde Hospital
Molde, Norway
Site recruitment: Not reported
Oslo University Hospital
Oslo, Norway
Site recruitment: Not reported
Bærum Hospital
Sandvika, Norway
Site recruitment: Not reported
University Hospital of North Norway
Tromsø, Norway
Site recruitment: Not reported
St. Olavs University Hospital
Trondheim, Norway
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

ClinicalTrials.gov · NCT03702140 · Registry updated: 2021-09-21

Condition / research focus: Osteoporosis
Sponsor: Shinshu University
Countries with listed sites: Japan
Registry dates and results: Start: 2018-10-09. Completion: 2025-10-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

"Teriparatide", "Forteo® or Teribon" (drug)

Where the study takes place — 1 listed sites

Yukio Nakamura
Matsumoto, Nagano, Japan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture

ClinicalTrials.gov · NCT05018637 · Registry updated: 2021-08-24

Condition / research focus: Vertebral Compression Fracture; Osteoporotic Fractures
Sponsor: Inbo Han
Countries with listed sites: South Korea
Registry dates and results: Start: 2020-09-01. Completion: 2022-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

WJ-MSC (drug) — also listed as: teriparatide
Teriparatide (drug)

Where the study takes place — 1 listed sites

CHA University, CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes

ClinicalTrials.gov · NCT04921124 · Registry updated: 2021-08-12

Condition / research focus: Stress Fracture
Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2021-05-24. Completion: 2021-07-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug)

Where the study takes place — 1 listed sites

Norfolk and Norwich University Hospitals Foundation Trust
Norwich, Norfolk, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot

ClinicalTrials.gov · NCT02023411 · Registry updated: 2021-06-30

Condition / research focus: Diabetic Neuropathic Arthropathy
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Countries with listed sites: India
Registry dates and results: Start: 2014-01. Completion: 2018-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: parathyroid hormone, recombinant human parathyroid hormone
Placebo (other)

Where the study takes place — 2 listed sites

Deptt of Endocrinology
Chandigarh, India
Site recruitment: Not reported
PGIMER
Chandigarh, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

ClinicalTrials.gov · NCT02824718 · Registry updated: 2021-06-28

Condition / research focus: Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment
Sponsor: Assistance Publique - Hôpitaux de Paris
Countries with listed sites: France
Registry dates and results: Start: 2017-06-06. Completion: 2020-05-28 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: FORSTEO
Thiazide (drug) — also listed as: ESIDREX
Potassium sparing diuretic (drug) — also listed as: MODAMIDE
Alfacalcidol (drug) — also listed as: UN-ALFA

Where the study takes place — 1 listed sites

AP-HP Hopital Europeen Georges Pompidou
Paris, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass

ClinicalTrials.gov · NCT04003467 · Registry updated: 2021-06-28

Condition / research focus: Osteoporosis
Sponsor: Entera Bio Ltd.
Countries with listed sites: Israel
Registry dates and results: Start: 2019-06-30. Completion: 2021-05-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

EBP05 (drug) — also listed as: hPTH(1-34), Teriparatide
Placebo of EBP05 (drug) — also listed as: Placebo

Where the study takes place — 4 listed sites

Hadassah Medical Center, Mt. Scopus Hospital
Jerusalem, Israel
Site recruitment: Not reported
Rabin Medical Center, Beilinson Campus
Petah Tikva, Israel
Site recruitment: Not reported
Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

ClinicalTrials.gov · NCT01679080 · Registry updated: 2021-06-25

Condition / research focus: Osteogenesis Imperfecta
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2012-11. Completion: 2021-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Zoledronic acid (drug) — also listed as: zolendronate, Aclasta
Teriparatide (drug) — also listed as: PTH, Forsteo
No active treatment (other)

Where the study takes place — 3 listed sites

Osteoporosis clinic; department of endocrinology and metabolism
Aarhus, Aarhus C, Denmark
Site recruitment: Not reported
Department of endocrinology
Hvidovre, Denmark
Site recruitment: Not reported
Department of Endocrinology M
Odense, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

ClinicalTrials.gov · NCT01292252 · Registry updated: 2021-05-03

Condition / research focus: Lumbar Spondylosis; Lumbar Spondylolisthesis; Adult Degenerative Lumbar Scoliosis
Sponsor: Shane Burch
Countries with listed sites: United States
Registry dates and results: Start: 2011-08. Completion: 2016-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

teriparatide (biological) — also listed as: Forteo, recombinant human parathyroid hormone (1-34)
Placebo (biological)

Where the study takes place — 1 listed sites

UCSF Spine Center
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults

ClinicalTrials.gov · NCT04747392 · Registry updated: 2021-02-10

Condition / research focus: Postmenopausal Osteoporosis
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2020-08-19. Completion: 2020-11-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SAL001 (biological)
FORSTEO (biological)

Where the study takes place — 1 listed sites

The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

ClinicalTrials.gov · NCT02176382 · Registry updated: 2021-02-09

Condition / research focus: Postmenopausal Osteoporosis
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2014-08. Completion: 2020-02 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

denosumab (drug) — also listed as: Prolia
teriparatide (drug) — also listed as: Forteo
Zoledronic acid (drug) — also listed as: Reclast

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Circulating Myokine Levels and Bone Metabolism

ClinicalTrials.gov · NCT04206618 · Registry updated: 2021-01-12

Condition / research focus: Osteoporosis, Postmenopausal
Sponsor: 424 General Military Hospital
Countries with listed sites: Greece
Registry dates and results: Start: 2019-06-01. Completion: 2020-11-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: rhPTH 1-34
Denosumab (drug) — also listed as: RANKL inhibitor

Where the study takes place — 1 listed sites

424 General Military Hospital
Thessaloniki, Northern Greece, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders

ClinicalTrials.gov · NCT02252679 · Registry updated: 2020-11-06

Condition / research focus: Bone Diseases; Osteomalacia; Osteoporosis
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium · Germany
Registry dates and results: Start: 2014-10. Completion: 2018-12 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 2 listed sites

UZ Leuven
Leuven, Belgium
Site recruitment: Not reported
GEOMAR-Helmholtz Centre for Ocean Research
Kiel, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →